✦ LIBER ✦

Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer

✍ Scribed by Suzuki, Yasuhiro; Ogiya, Rin; Oshitanai, Risa; Terao, Mayako; Terada, Mizuho; Morioka, Toru; Tsuda, Banri; Niikura, Naoki; Okamura, Takuho; Saito, Yuki; Tokuda, Yutaka

Book ID: 121638648
Publisher: Springer
Year: 2013
Tongue: English
Weight: 288 KB
Volume: 19
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-013-0547-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase IIa Trial of Trastuzumab Emtansine

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer

✍ Miller, K. D.; Dieras, V.; Harbeck, N.; Andre, F.; Mahtani, R. L.; Gianni, L.; A 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 148 KB

Phase II Randomized Study of Trastuzumab

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

✍ Hurvitz, S. A.; Dirix, L.; Kocsis, J.; Bianchi, G. V.; Lu, J.; Vinholes, J.; Gua 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

Adding hormonal therapy to chemotherapy

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

✍ Naoki Hayashi, Naoki Niikura, Hideko Yamauchi, Seigo Nakamura, Naoto T. Ueno 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 279 KB

Limited human epidermal growth factor re

Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study

✍ van Rooijen, J.M.; de Munck, L.; de Graaf, J.C.; Siesling, S.; de Vries, E.G.; B 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 384 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

The potential for trastuzumab emtansine

The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies

✍ Hurvitz, S. A.; Kakkar, R. 📂 Article 📅 2012 🏛 SAGE Publications 🌐 English ⚖ 775 KB